cemka > Publications > Biometry and database analysis

Sort publications on year

  • Biometry and database analysis

    Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients – A nationwide study of health insurance claims data

    CHARRIERE S, MAILLOT F, BOUEE S, DOUILLARD C, JACOB C, MAREN SCHNEIDER K, THEIL J, ARNOUX J-B.

    Molecular Genetics and Metabolism ; 2023;139(3):107625

  • Biometry and database analysis

    Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis

    MATHURIN P, DE ZELICOURT M, LAURENDEAU C, DHAOUI M, KELKOULI N, BLANC J-F.

    Clin Res Hepatol Gastroenterol ; 2023;47(5):102124

  • Biometry and database analysis

    Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data

    FAGNANI F, LAURENDEAU C, DE ZELICOURT M, MARSHALL J.

    Epilepsia Open ; 2022;7(4):633-644

  • Biometry and database analysis

    Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

    HARROW B, FAGNANI F, NEVORET C, TRUONG-THANH XM, DE ZÉLICOURT M, DE MESTIER L.

    Adv Ther ; 2022;39:1754-1771

  • Biometry and database analysis

    Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

    WEIL-OLIVIER C, TAHA MK, BOUEE S, EMERY C, LONCLE-PROVOT V, NACHBAUR G, BECK E, PRIBIL C.

    Human Vaccines & Immunotherapeutics ; 2022;18(1):2021764

  • Biometry and database analysis

    Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis.

    NEUZILLET C, EMERY C, TEISSIER C, BOUEE S, LIEVRE A.

    Lancet Reg Health Eur ; 2022;15:100324

  • Biometry and database analysis

    Costs and management of patients with hemophilia A in France: the Hemraude study.

    LAURENDEAU C, GOUDEMAND J, TROSSAERT M, POLACK B, VARIN R, GODARD C, HADIM F, DETOURNAY B.

    Eur J Health Econ. ; 2022;23(1):23-32

  • Biometry and database analysis

    Correction to: Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM)

    SHEN J, BOUEE S, ARIS E, EMERY C, BECK EC.

    Infect Dis Ther ; 2022;11(1):263-264

  • Biometry and database analysis

    Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claim database analysis.

    CORTET B, SCHOTT AM, DESAMERICQ G, CHAUNY JV, SAMAMA P, EMERY C, FAGNANI F.

    Bone ; 2022;154:116255

  • Biometry and database analysis

    Non‑tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

    VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.

    BMC Infectious Diseases ; 2021;21(1):1165

  • Biometry and database analysis

    Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases.

    MISERY L, BRENAUT E, TORRETON E, BONTE J, BOUEE S.

    Journal of the European Academy of Dermatology and Venereology ; 2021;35(9):e602-e604

  • Biometry and database analysis

    Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database

    TAHA M.-K , WEIL-OLIVIER C , BOUEE S, EMERY C , NACHBAUR G, PRIBIL C, LONCLE-PROVOT V.

    HUMAN VACCINES & IMMUNOTHERAPEUTICS ; 2021;17(6):1858-1866

  • Biometry and database analysis

    Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database

    WEIL-OLIVIER C, TAHA M-K, EMERY C, BOUEE S, BECK E, ARIS E, LONCLE-PROVOT V, NACHBAUR G, PRIBIL C.

    Infectious Diseases and Therapy ; 2021;10:1607–1623

  • Biometry and database analysis

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C

    Future Oncol ; 2020;16(16),1115-1124

  • Biometry and database analysis

    An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017

    VERMERSCH P, SUCHET L, COLAMOARINO R, LAURENDEAU C, DETOURNAY B

    Mult Scler Relat Disord ; 2020;46